



brainstorm
cell therapeutics

BrainStorm Cell Therapeutics

NASDAQ: BCLI

COMPANY UPDATE

Chaim Lebovits, CEO


March 8, 2018

Forward Looking Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at <http://www.sec.gov>.

These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

2017-2018 Progress



Leveraging Core Company Capabilities

Manufacturing excellence

- NurOwn Cryopreservation
- Manufacturing Capabilities

Strategic Partnerships

- California Institute for Regenerative Medicine (CIRM)





Strong Science

- Cell and disease biology
- Industry CNS experience

Patient Focus


- Patient Advocacy Leadership

NurOwn® Technology




NurOwn® Product Characteristics

NurOwn®




Placebo




Mean ± SEM
 * p < 0.05 ** p < 0.01 *** p < 0.001

↑Neuroprotection


↓Neuro-inflammation



NurOwn®





Placebo




■ Pre transplantation
 ■ Post transplantation

NurOwn® successfully evaluated in preclinical models of neurodegenerative disease


Huntington's Disease




Parkinson's Disease



Autism



Multiple Sclerosis



High Unmet Need Across Neurodegenerative Disorders

	Amyotrophic Lateral Sclerosis (ALS)	Parkinson's Disease (PD)	Progressive Multiple Sclerosis (MS)	Alzheimer's Disease (AD)	Huntington's Disease (HD)	Autism Spectrum Disorder (ASD)
Global patients	220,000	10,000,000	1,250,000	47,000,000	300,000	35,000,000
US patients	20,000	1,000,000	200,000	5,000,000	30,000	3,500,000
Clinical study endpoints	ALSFRS-R SVC	UPDRS	EDSS MSFC	ADAS-COG CDR-SB MOCA	UHDRS	ADOS-G CARS GARS
Biomarkers	CSF MCP-1 CSF CHIT-1 CSF NfL	Dopamine transporter imaging	MRI CSF sCD27 CSF CHIT-1 CSF NfL	CSF Tau CSF AB-42 CSF NfL PET	CSF NfL CSF Tau CSF mHTT	CSF BDNF CSF MCP-1

Global Prevalence of ALS Increasing (2015-2040)




Figure 2 | Projected increase in the number of individuals with ALS in developed and developing countries from 2015 to 2040. The bar graph on the left shows the increase in cases in developed (green) and developing (blue) countries from 2015 to 2040. The graph on the right shows the projected number of cases in each country in 2040. The graph was created in R using the packages ggplot2 and ggsupplot (available at <https://cran.r-project.org/>).

Rich IP portfolio- Strengthened November 2017 with US Notice of Allowance to Include Parkinson's Disease

Patent Name/ Int. App. No.	Pending Jurisdictions	Allowed Jurisdictions	Granted Jurisdictions	Expiry Date
ISOLATED CELLS AND POPULATIONS COMPRISING SAME FOR THE TREATMENT OF CNS DISEASES/PCT/IL2006/000699	US		Europe, US	2030
MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CNS DISEASES PCT/IL2009/000525	Hong Kong	Europe	US, Israel,	2032
METHODS OF GENERATING MESENCHYMAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS / PCT/IL2013/050660	US, Europe, Hong Kong, Israel, Canada, Brazil, Japan			2038
METHOD OF QUALIFYING CELLS /PCT IL2015/050159	US, Europe, Hong Kong, Israel, Canada, Brazil, Japan			2040
Methods of treating ALS PCT/IL2017/050801	PCT			2042

NurOwn® Regulatory Status

Orphan Drug Designation

- US and EU

Fast Track Designation

- US

2017 P&L Report

	2017	2016
Operating expenses		
Research and development, net	977 (*)	2,250
General and administrative	4,022	2,833
Operating loss	4,999	5,083
Financial income	47	101
Net loss	4,952	4,982
Basic and diluted net loss per share from continuing operations	0.26	0.27

(*) Research and development expenses excluding grants were \$6,795,000 in 2017, compared with \$3,435,000 in 2016.

2017 P&L Report

	2017	2016
Operating expenses		
Research and development, net	977 (*)	2,250
General and administrative	4,022	2,833
Operating loss	4,999	5,083
Financial income	47	101
Net loss	4,952	4,982
Basic and diluted net loss per share from continuing operations	0.26	0.27

(*) Research and development expenses excluding grants were \$6,795,000 in 2017, compared with \$3,435,000 in 2016.

2017 P&L Report



	2017	2016
Operating expenses		
Research and development, net	977 (*)	2,250
General and administrative	4,022	2,833
Operating loss	4,999	5,083
Financial income	47	101
Net loss	4,952	4,982
Basic and diluted net loss per share from continuing operations	0.26	0.27

(*) Research and development expenses excluding grants were \$6,795,000 in 2017, compared with \$3,435,000 in 2016.


2017 Balance Sheet

	Dec. 31 st , 2017	Dec. 31 st , 2016
Current Assets		
Cash and Cash equivalents	2,483	547
Short-term deposit	5,273	9,443
Account receivable	672	306
Prepaid expenses	1,195	148
Total Current Assets	9,623	10,444
Long-Term Assets	1,800	322
Total Assets	11,423	10,766

NurOwn[®] ALS Development- Update



NurOwn® Phase 3 Randomized ALS Study* (BCT-002-US)- Status and Timelines



* Supported by \$16M CIRM CLIN-2 grant

Recent additions to Brainstorm's Board of Directors

Arturo Arraya MA, BS, MBA

- Formerly Vice President and Head of Global Commercial for Novartis' Cell and Gene Therapies Unit

June S. Almenoff MD PhD

- Formerly President and CMO of Furiex Pharmaceuticals.

Tony Polverino PhD

- CSO Kite Pharmaceuticals

Management Team

Chaim Lebovits
President and CEO

Ralph Kern, MD, MHSc.
COO and CMO

Eyal Rubin
EVP, CFO

Mary Kay Turner
VP, Patient Advocacy and
Government Affairs

Yael Gothelf PhD.
VP, Scientific and Regulatory Affairs

Uri Yablonka
SVP, Chief Business Officer

Yossef Levy PhD.
VP, Cell Production

Revital Aricha PhD.
VP, R&D



brainstorm
cell therapeutics

BrainStorm Cell Therapeutics

NASDAQ: BCLI

Thank You